Recent studies have shown that SGLT2 inhibitors increase plasma renin and total urinary angiotensinogen/creatinine ratio in patients with type 1 diabetes.17 21 These results suggest that treatment with an SGLT2 inhibitor stimulates RAS activity in the kidney. This evidence concerns the gene SLC5A2 and type 1 diabetes mellitus.